Relation of Peripheral Collagen Markers to Death and Hospitalization in Patients With Heart Failure and Preserved Ejection Fraction: Results of the I-PRESERVE Collagen Substudy
暂无分享,去创建一个
R. McKelvie | J. McMurray | H. Krum | M. Komajda | B. Massie | M. Zile | P. Carson | I. Anand | H. Schneider | M. Elsik | A. Ptaszynska | M. Black
[1] H. Krum,et al. Abstract 315: Directly Targeting Myocardial Fibrosis with FT-011 Improves Cardiac Remodeling in Experimental Diabetic Cardiomyopathy , 2008 .
[2] J. Emparanza,et al. Serum carboxy-terminal propeptide of procollagen type I is a marker of myocardial fibrosis in hypertensive heart disease. , 2000, Circulation.
[3] C. Jellis,et al. Assessment of nonischemic myocardial fibrosis. , 2010, Journal of the American College of Cardiology.
[4] P. Marino,et al. Amino-terminal propeptide of type III procollagen is associated with restrictive mitral filling pattern in patients with dilated cardiomyopathy: a possible link between diastolic dysfunction and prognosis , 2004, Heart.
[5] Daniel Levy,et al. Relation of Disease Pathogenesis and Risk Factors to Heart Failure With Preserved or Reduced Ejection Fraction: Insights From the Framingham Heart Study of the National Heart, Lung, and Blood Institute , 2009, Circulation.
[6] N. Afdhal,et al. Hepatic fibrosis: Are any of the serum markers useful? , 2001, Current gastroenterology reports.
[7] Arantxa González,et al. Increased Collagen Type I Synthesis in Patients With Heart Failure of Hypertensive Origin: Relation to Myocardial Fibrosis , 2004, Circulation.
[8] D. Phelan,et al. Natural history of markers of collagen turnover in patients with early diastolic dysfunction and impact of eplerenone. , 2009, Journal of the American College of Cardiology.
[9] Arantxa González,et al. Biochemical assessment of myocardial fibrosis in hypertensive heart disease. , 2001, Hypertension.
[10] M. Schellings,et al. Matricellular proteins in the heart: possible role during stress and remodeling. , 2004, Cardiovascular research.
[11] K. Weber,et al. Collagen metabolism in cultured adult rat cardiac fibroblasts: response to angiotensin II and aldosterone. , 1994, Journal of molecular and cellular cardiology.
[12] R. McKelvie,et al. The irbesartan in heart failure with preserved systolic function (I-PRESERVE) trial: rationale and design. , 2005, Journal of cardiac failure.
[13] M. Volpe,et al. Plasma osteopontin reveals left ventricular reverse remodelling following cardiac resynchronization therapy in heart failure. , 2011, International journal of cardiology.
[14] W. Paulus,et al. Molecular determinants of heart failure with normal left ventricular ejection fraction , 2009, Pharmacological reports : PR.
[15] D. M. Keenan,et al. Mechanisms of ensemble failure of the male gonadal axis in aging. , 2005, Journal of endocrinological investigation.
[16] F. Pagani,et al. Markers of bone turnover: biochemical and clinical perspectives. , 2005, Journal of endocrinological investigation.
[17] Kenneth McDonald,et al. Diastolic Heart Failure: Evidence of Increased Myocardial Collagen Turnover Linked to Diastolic Dysfunction , 2007, Circulation.
[18] Susan Anderson,et al. Irbesartan in patients with heart failure and preserved ejection fraction. , 2008, The New England journal of medicine.
[19] M. Senni,et al. Heart failure with preserved systolic function. A different natural history? , 2001, Journal of the American College of Cardiology.
[20] F. Alla,et al. Limitation of Excessive Extracellular Matrix Turnover May Contribute to Survival Benefit of Spironolactone Therapy in Patients With Congestive Heart Failure: Insights From the Randomized Aldactone Evaluation Study (RALES) , 2000, Circulation.